NCT06586203 (GENOCORDIA) is a NA clinical trial of Polygenic Risk Score in Diabetes Mellitus, Type 2, sponsored by Optithera.

Who is sponsoring NCT06586203?

NCT06586203 is sponsored by Optithera.

What drugs are being tested in NCT06586203?

Interventions in NCT06586203: Polygenic Risk Score.

What condition does NCT06586203 study?

NCT06586203 studies Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2.

Is NCT06586203 still recruiting?

NCT06586203 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06586203: GENOCORDIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

Recruiting now NA Last updated 19 September 2024

What this trial tests

NA trial testing Polygenic Risk Score in Diabetes Mellitus, Type 2 in 2,714 participants. Currently enrolling.

Timeline

23 August 2024

Primary endpoint
23 August 2027

23 August 2028

Quick facts

Lead sponsor	Optithera
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	2,714
Start date	23 August 2024
Primary completion	23 August 2027
Estimated completion	23 August 2028
Sites	2 locations across Canada

Drugs / interventions tested

Polygenic Risk Score

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Diabetic Nephropathy Type 2 — all drugs for Diabetic Nephropathy Type 2 →

Sponsor

Optithera

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2 or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets. This will be demonstrated as a significant improvement in a composite value including HbA1c or systolic blood pressure (SBP) or albuminuria (UACR), or glomerular filtration rate (GFR) lowering. Researchers will compare the recommended therapeutic targets of uninformed and informed patients to see if the knowledge of the risk by the patients and their treating physicians improves achievement of these targets. Participants will: Have a saliva sampling to determine the genetic risk. Visit the clinic once every 3 months for checkups and tests Answer two questionnaires on quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Polygenic Risk Score

Trials testing the same drug.

NCT06911294 — Feasibility of Innovative Approaches for Personalized Cardiovascular Prevention · NA · recruiting
NCT04604353 — Early Detection of Coronary Artery Disease by Polygenic and Metabolic Risk Scoring · NA · completed
NCT04474834 — Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study · active not recruiting

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06586203 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Optithera
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06586203.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing